Atypical Actives Gain Attention - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Atypical Actives Gain Attention
Clarifying GMPs for excipients used as actives.


Pharmaceutical Technology
Volume 35, pp. s41-s42

Part of this problem is due to a lack of communication between final dosage-form drug manufacturers and excipient manufacturers—it is often the case that the excipient manufacturer and/or supplier do not know the use of a particular excipient. Industry and regulators are trying to improve this dialogue through various transparency and information-sharing initiatives.

But the bottom line is that excipient manufacturers and suppliers do not want to have to upgrade their facilities or processes to adhere to ICH Q7 for excipients used as atypical actives, especially when they have little business interest in selling their excipient products for these purposes. The additional controls, documentation, and cost, in most cases, would not be worth their return on investment. As a result, they may turn away from the pharmaceutical industry and this action could lead to a shortage of supply of the atypical actives. This would be a huge problem, says Schoneker, because it could force many drug manufacturers to have to reformulate their products or it could lead to the removal from the marketplace of many commonly used products.

To address these growing concerns, IPEC has been working with PDA and other industry stakeholders to develop a guideline specifically for atypical actives that would ultimately have FDA buy-in. Some potential solutions, says Schoneker, would involve having regulatory flexibility related to GMP expectations for existing atypical actives that have been used for years without safety problems. For atypical actives used in drug products, use of the IPEC–PQG excipient GMP guide, would be an appropriate GMP to use. There may be situations where additional technical considerations or specifications are required depending on the specific aspects of a particular material and its use. These details would need to be negotiated between the excipient manufacturer and the final drug-product manufacturer based on the material's intended use, he explains. Additional technical considerations and specifications, however, are not a higher level of GMP. The separation of the two definitions needs to be discussed among industry and regulatory authorities.

"We need to have a resolution that is acceptable to excipient makers, users, and regulators that makes them feel comfortable that appropriate controls are in place and that provides security to makers and users that they are not in a position of liability," says Schoneker.

IPEC's working group on atypical actives is in the process of working through this subject and will be presenting ideas and discussions at various upcoming industry meetings. For more information, please contact IPEC–Americas at
.

Reference

1. ICH, Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients (2000).

2. IPEC–PQG, GMP Guide for Pharmaceutical Excipients (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here